BERLIN (Reuters) – Bayer said that new data presented on Monday highlighted the potential of finerenone, compared with a placebo, to reduce the incidence of sudden cardiac death in a broad range of patients, including early and late stages of chronic kidney disease associated with type 2 diabetes.
(Writing by Miranda Murray; Editing by Paul Carrel)
